E. Alemao
YOU?
Author Swipe
View article: Predictors of first hospitalization due to disease activity and infections in systemic lupus erythematosus patients
Predictors of first hospitalization due to disease activity and infections in systemic lupus erythematosus patients Open
Objectives To identify the predictive factors of first hospitalization and associated variables to the main causes of hospitalizations in lupus patients from a Latin American cohort. Methods The first hospitalization after entry into the c…
View article: Risk of adverse events in patients with bullous pemphigoid treated with oral corticosteroids in the United States
Risk of adverse events in patients with bullous pemphigoid treated with oral corticosteroids in the United States Open
Background The potential association of long‐term oral corticosteroid (OCS) use with adverse events (AEs) in patients with bullous pemphigoid (BP) is not well characterized in a real‐world setting. Objectives To evaluate the effect of OCS …
View article: P1697: CHARACTERISTICS, TREATMENT PATTERNS AND HEALTHCARE UTILIZATION OF PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA INITIATING FIRST LINE THERAPY OF ORAL CORTICOSTEROIDS WITH OR WITHOUT RITUXIMAB
P1697: CHARACTERISTICS, TREATMENT PATTERNS AND HEALTHCARE UTILIZATION OF PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA INITIATING FIRST LINE THERAPY OF ORAL CORTICOSTEROIDS WITH OR WITHOUT RITUXIMAB Open
Topic: 36. Ethics and health economics Background: Warm autoimmune hemolytic anemia (wAIHA) is a rare life-threatening disorder caused by autoantibodies that lead to the premature destruction of healthy red blood cells. Due to a paucity of…
View article: AB0612 THE RELATIONSHIP BETWEEN SYSTEMATIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) AND HEALTHCARE RESOURCE UTILIZATION AND COSTS IN LUPUS PATIENTS
AB0612 THE RELATIONSHIP BETWEEN SYSTEMATIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI) AND HEALTHCARE RESOURCE UTILIZATION AND COSTS IN LUPUS PATIENTS Open
View article: POS0477 RELATIONSHIP BETWEEN SHARED EPITOPE STATUS AND REFRACTORY RHEUMATOID ARTHRITIS
POS0477 RELATIONSHIP BETWEEN SHARED EPITOPE STATUS AND REFRACTORY RHEUMATOID ARTHRITIS Open
View article: POS1236 TREATMENT TRAJECTORIES IN IDIOPATHIC INFLAMMATORY MYOPATHIES
POS1236 TREATMENT TRAJECTORIES IN IDIOPATHIC INFLAMMATORY MYOPATHIES Open
View article: Identifying Potentially Undiagnosed Nontuberculous Mycobacterial Lung Disease Among Patients with Chronic Obstructive Pulmonary Disease: Development of a Predictive Algorithm Using Claims Data
Identifying Potentially Undiagnosed Nontuberculous Mycobacterial Lung Disease Among Patients with Chronic Obstructive Pulmonary Disease: Development of a Predictive Algorithm Using Claims Data Open
View article: Incremental Mortality Associated with Nontuberculous Mycobacterial Lung Disease Among US Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease
Incremental Mortality Associated with Nontuberculous Mycobacterial Lung Disease Among US Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Open
RATIONALE Nontuberculous mycobacterial lung disease (NTMLD) is an uncommon mycobacterial infection whose prevalence has increased over the last decade.Many patients with NTMLD have comorbid respiratory diseases such as COPD.Treatment of NT…
View article: Cycling of tumor necrosis factor inhibitors <i>versus</i> switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis
Cycling of tumor necrosis factor inhibitors <i>versus</i> switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis Open
Introduction: For patients with rheumatoid arthritis (RA) with an inadequate response to tumor necrosis factor inhibitors (TNFi), main options include cycling onto a different TNFi or switching to a biologic/targeted synthetic disease-modi…
View article: AB0400 PATIENT-REPORTED OUTCOME MEASURES IN SWEDISH PATIENTS WITH RECENT-ONSET SLE VERSUS RA IN THE FIRST 60 MONTHS AFTER DIAGNOSIS
AB0400 PATIENT-REPORTED OUTCOME MEASURES IN SWEDISH PATIENTS WITH RECENT-ONSET SLE VERSUS RA IN THE FIRST 60 MONTHS AFTER DIAGNOSIS Open
View article: Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry
Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry Open
View article: Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery
Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery Open
View article: Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus
Relationship between remission, disease activity and patient-reported outcome measures in patients with recent-onset systemic lupus erythematosus Open
Objective Definitions of remission in systemic lupus erythematosus (SLE; DORIS (1A/1B/2A/2B)), disease activity assessments and patient-reported outcome measures (PROMs) are useful in shared decision making between patients with SLE and ph…
View article: Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry
Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry Open
View article: Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials
Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials Open
Understanding the correlation between transplant symptoms, health-related quality of life (HRQoL), and graft outcomes is needed to support patient-focused drug development and posttransplant management. A post-hoc analysis of patient-repor…
View article: Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus
Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus Open
Objective Examinations of Patient‐Reported Outcomes Measurement Information System ( PROMIS ) measures in adult systemic lupus erythematosus ( SLE ) have provided support for their cross‐sectional validity in SLE . We estimated responsiven…
View article: Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE) Open
Bristol-Myers Squibb.
View article: Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis
Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis Open
Objective: To characterize the rate of healthcare resource utilization (HCRU) between anti-cyclic citrullinated peptide (CCP; a surrogate for anti-citrullinated protein antibodies [ACPAs]) positive (+) patients with rheumatoid arthr…
View article: Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease‐Modifying Antirheumatic Drugs: Results From a Real‐World Study
Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease‐Modifying Antirheumatic Drugs: Results From a Real‐World Study Open
Objective Seropositivity for anti–citrullinated protein antibody ( ACPA )/rheumatoid factor ( RF ) in rheumatoid arthritis ( RA ) is associated with increased overall mortality; however, the association between antibody titers and mortalit…
View article: Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach
Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach Open
Objective Previous attempts to estimate rheumatoid arthritis ( RA ) disease activity using claims data only did not yield high performance. We aimed to assess whether supplementing claims data with readily available electronic medical reco…
View article: Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry Open
View article: SAT0086 EVALUATION OF MEDICATION PERSISTENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH NON-TNFI DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
SAT0086 EVALUATION OF MEDICATION PERSISTENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH NON-TNFI DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS Open
View article: AB0509 PREVALENCE AND INCIDENCE OF SJÖGREN'S SYNDROME AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-WORLD COMMUNITY PRACTICE SETTINGS
AB0509 PREVALENCE AND INCIDENCE OF SJÖGREN'S SYNDROME AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-WORLD COMMUNITY PRACTICE SETTINGS Open
View article: AB0360 EVALUATION OF HEALTHCARE RESOURCE UTILISATION AND COSTS OF SJöGREN'S SYNDROME: PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT OR ANTI-TNF DMARDS
AB0360 EVALUATION OF HEALTHCARE RESOURCE UTILISATION AND COSTS OF SJöGREN'S SYNDROME: PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT OR ANTI-TNF DMARDS Open
View article: SAT0072 EVALUATION OF RHEUMATOID ARTHRITIS TREATMENTS AND JOINT OUTCOMES IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
SAT0072 EVALUATION OF RHEUMATOID ARTHRITIS TREATMENTS AND JOINT OUTCOMES IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE Open
View article: AB0373 A COMPARATIVE EFFECTIVENESS STUDY OF ABATACEPT AND TNFI AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING REAL-WORLD DATA
AB0373 A COMPARATIVE EFFECTIVENESS STUDY OF ABATACEPT AND TNFI AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING REAL-WORLD DATA Open
View article: AB0770 SYMPTOMS AND IMPACTS IN PSORIATIC ARTHRITIS: FINDINGS FROM QUALITATIVE PATIENT INTERVIEWS
AB0770 SYMPTOMS AND IMPACTS IN PSORIATIC ARTHRITIS: FINDINGS FROM QUALITATIVE PATIENT INTERVIEWS Open
View article: THU0110 DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RA WITH SJÖGREN'S SYNDROME ENROLLED IN A LARGE OBSERVATIONAL US REGISTRY
THU0110 DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RA WITH SJÖGREN'S SYNDROME ENROLLED IN A LARGE OBSERVATIONAL US REGISTRY Open
View article: Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty
Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty Open
Rheumatology Research Foundation, National Institutes of Health, and Bristol-Myers Squibb.
View article: Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis
Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis Open
This research and manuscript were funded by Bristol-Myers Squibb (BMS). Alemao and Connolly are employees and shareholders of BMS and participated in the design of the study, interpretation of the data, review/revision of the manuscript, a…